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Abstract
Background: Herpes zoster (HZ) is a common disease, characterized by rash-associated localized pain. Its main
complication, post-herpetic neuralgia (PHN), is difficult to treat and may last for months to years in the wake of
rash resolution. Uncertainties remain as to the knowledge of predictors of HZ-related pain, including the role of
antiviral therapy in preventing PHN in ordinary clinical practice. This prospective cohort study was aimed at
investigating pain intensity at HZ presentation and its correlates, as well as the incidence of PHN and its predictors.
Methods: Patients diagnosed with HZ were consecutively enrolled by a network of Italian General Practitioners
and Hospital Units in the health district of Pescara, Italy, over two years. Uncertain cases were referred for
microbiological investigation. Data were collected through electronic case report form (e-CRFs) at enrolment and at
1, 3, 6 and 12 months after enrolment. Pain intensity was coded on a five-degree semi-quantitative scale at each
time point. PHN was defined as pain of any intensity during follow-up and quantified using an area-under-the-
curve (AUC) method.
Results: Four hundred and forty-one patients composed the final sample. Mean age was 58.1 years (SD = 20.4
years); 43.5% of patients were males; 7.9% did not receive prescription of antivirals. Intense/very intense pain at
presentation was reported by 25.2% of patients and was significantly associated with female gender, older age,
cigarette smoking, trauma and/or surgery at HZ site (logistic regression). PHN was diagnosed in 51.2% of patients
at one month and in 30.0% of patients at three months. PHN was significantly associated with pain intensity at
presentation, age, smoking, trauma and missed antiviral prescription (generalized estimating equations model). The
same factors were also independent predictors of the overall pain burden as described by the AUC method (linear
regression).
Conclusions: Smoking, traumas and surgery at the HZ site emerged as new predictors of both HZ-related pain
intensity and persistence, opening new perspectives in the prevention of HZ-related pain. An independent line of
evidence was provided for the efficacy of antiviral therapy in preventing PHN and reducing total pain burden.
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Herpes zoster (HZ) is a common disease, characterized
by localized, monolateral pain and vesicular rash, due to
the reactivation of latent varicella-zoster virus (VZV),
with an incidence of 2.2 to 5.2 cases/1,000 patient-years
[1-7]. Although HZ is often mild and self limiting
[1,4,5,8,9], pain at presentation has been reported as
i n t e n s eo rv e r yi n t e n s ei nar e m a r k a b l ep r o p o r t i o no f
patients [3,5]. Pain at presentation, however, has rarely
been quantified, and its correlates have been poorly
explored [10-12]. The main complication of HZ is repre-
sented by long lasting and/or relapsing pain at the site of
rash, termed post-herpetic neuralgia (PHN), which is dif-
ficult to treat and may last for months to years, especially
in people aged over 65 [9,13-16]. A better knowledge of
the acute pain correlates, as well as of predictors of PHN
may ultimately facilitate their prevention. Pain intensity
at rash onset, age, rash severity, length of prodromal pain
and cranial localization were more frequently reported as
predictors of PHN [1,9,17-21]. At present, little is known
o nt h ep o s s i b l er o l eo ft r a u m aa n ds u r g e r ya tt h es i t eo f
VZV reactivation [22-26]. Similarly, uncertainties remain
on the role of antiviral therapy for both controlling acute
pain and preventing PHN in ordinary clinical settings,
because most data on antivirals in HZ came from trials
selectively enrolling patients diagnosed ≤ 72 hours after
disease onset [27]. As a consequence, the usefulness of
antiviral therapy in HZ has been questioned until
recently [4,5,8,27,28]. Finally, although smoking can have
immunomodulatory effects and, therefore, influence the
pathogenesis of latent reactivation infections [29], its
association with PHN has never been formally
investigated.
We carried out a prospective, monocentric cohort
study, enrolling a large sample of consecutive unselected
patients with HZ, in order to evaluate intensity of pain
at presentation, pain persistence during follow-up and
the overall pain burden, as well as several potential cor-
relates of pain intensity at presentation and predictors
of PHN.
Methods
Study population and design
A network was established among 41 general practi-
tioners (GPs) in the district of Pescara, Italy. Between 1
May 2006, and 30 April 2008, GPs enrolled all incident
cases of HZ observed. In addition to GPs, the Infectious
Diseases (ID) Unit, the Dermatology Unit, and the
Department of Pain Medicine and Palliative Care,
shortly Pain Management Clinic (PMC) of the Pescara
General Hospital, Pescara, Italy, reported consecutive
data on HZ patients observed. Enrolling physicians were
connected through a dedicated software, avoiding
repeated enrolments. The study was approved by the
local Ethics Committee. Enrolling physicians were
requested to report prescribed antivirals and untreated
cases; they were suggested to prescribe antivirals when-
ever active lesions were present, in accordance with cur-
rent local trends in prescription. An informed consent
was signed by patients at enrolment, and an e-CRF was
filled in with demographic and clinical information. One
or more pictures of lesions were also included for
patients consenting to be pictured, to allow expert
review. A one-year follow-up was planned for enrolled
cases.
Diagnosis of herpes zoster
Diagnosis of HZ was clinical whenever enrolling physi-
cians felt it appropriate, with no additional evidence
needed. Patients were enrolled whatever the stage of the
rash and the time interval from the rash onset. The
extent of the rash was codified as mild-moderate or
severe according to the number of lesions (respectively,
<5 0a n d≥ 50), defined as papules, vesicles or crusted
vesicles [19]. When GPs felt that laboratory investigation
should be performed, uncertain cases were referred to
the ID Unit for evaluation within 24 to 48 hours. Review
of clinical data was provided, together with microbiolo-
gical investigation by assays of both IgG and IgM
VZV-specific antibodies, as well as by assays of plasma
samples, vesicle eluates and other specimens as appro-
priate by Real Time VZV DNA PCR (Polymerase Chain
Reaction, Nanogen
©, Italy) [30,31].
Pain intensity at presentation
HZ patients were asked about pain severity at presenta-
t i o n ,a sw e l la sa te v e r yf u r t her visit or phone call. Fol-
low up visits or phone calls were performed at 1, 3, 6
and 12 months after enrolment. Pain intensity was
coded on a five-degree semi-quantitative scale (including
no pain, mild, moderate, intense or very intense pain).
All patients reporting intense or very intense pain were
granted immediate access to PMC. Use of analgesics
(NSAIDs, paracetamol or tramadol) at enrolment was
reported. Adverse events other than pain were classified
according to the Common Terminology Criteria for
Adverse Events, Version 3.0, USA [32].
Qualitative and quantitative diagnosis of Post Herpetic
Neuralgia
PHN was defined as the presence of pain of any inten-
sity at follow-up visits, measured with the above
described scale. At each follow-up visit or phone call
patients were asked to report on the worst pain intensity
experienced since their last visit or phone call, possibly
specifying the time of occurrence within the interval. To
take into account the total burden of pain in the indivi-
dual patient, pain during follow-up was quantified using
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proposed by Coplan et al. [ 3 3 ] .B r i e f l y ,w ec o m b i n e d
measures of pain intensity and duration, and each
patient’sA U Cw a sc a l c u l a t e da st h es u mo fa l la r e a s
obtained by multiplying the average of two consecutive
pain scores by the number of days between the scores.
Correlates of pain intensity at presentation and predictors
of PHN
A number of potential correlates of pain intensity at
presentation and predictors of PHN were evaluated: age;
gender; familial status (single, married or divorced); edu-
cational level (lower, no education or primary school;
higher, any diploma or degree); hypertension; diabetes
mellitus; HCV and/or HIV infection; alcohol abuse
(binge drinking or ≥ 80 grams daily); current or former
cigarette smoking (current, ≥ 1 cigarette daily, for ≥ 5
years; former, if patients smoked as defined above for at
least 5 years quitting ≤ 2 years before presentation);
familial history of major cardiovascular events (occurred
in first degree relatives aged ≤ 60 years); malignancies,
neurological diseases, major depression or psychiatric ill-
nesses, allergy (any past reaction to environmental, ali-
mentary or cutaneous antigens). Clinical history was
considered positive for trauma when patients recalled
a n yt y p eo ft r a u m aa tt h es i t eo fl e s i o n s( c o n t u s i o n s ,
burnings, wounds, politraumas involving the reactivation
site) up to six months ahead of enrolment. Surgical
interventions at the site of lesions were considered
whenever performed. Other potential predictors were:
site of lesions, pain intensity at presentation, rash sever-
ity and prescribed NSAIDs. Finally, patients prescribed
antivirals were compared to those not prescribed anti-
viral therapy for any reason.
Data analysis
Initial descriptive statistics were used to analyse the dis-
tribution of PHN cases in the sample and according to
all variables investigated. Logistic regression was used to
evaluate potential independent predictors of intense/
very intense pain at presentation (as compared to mild/
moderate pain), as well as to investigate potential pre-
dictors of PHN at one or three months (two separate
models). In all models, covariates were included in a
stepwise forward process with the following inclusion
criteria: P < 0.15 at univariate analysis; change in signifi-
cant odds ratios (OR) > 20%; age and gender forced to
entry. Standard post-estimation tests were used to assess
final model validity (Hosmer-Lemeshow test for evalua-
tion of the goodness of fit, area under the ROC curve
for predictive power [34]), performing multicollinearity
(using Spearman coefficients) and influential observation
analyses (using standardized residuals, change in Pear-
son and deviance chi-square [35]), and testing for
potential interaction and higher power terms. The
model predicting pain at presentation was repeated
excluding seven influential observations with no relevant
differences. The models predicting PHN at one and
three months were repeated excluding 14 and 11 influ-
ential observations, respectively, with no substantial var-
iations. Separate logistic models for the time points 6
and 12 months were not fitted because of the small
number of successes (n = 43 and n = 33, respectively),
with high potential for overfitting. However, the data
from 6- and 12-month visits were included in a general-
ized estimating equations (GEE) model, set as a repeated
measures logistic regression (logit link and binomial
family), which was performed to investigate the potential
interactions between time and each of the potential
PHN predictors [36]. The model was fitted assuming an
exchangeable correlation structure, with robust standard
errors (based upon sandwich estimator) [37]. Time was
included in the model either as an ordinal variable or
using dummy variables for each visit (a one-month visit
being the reference category). Given that all dummy
ORs were significantly associated with PHN and were
quite linearly decreasing, time was treated as ordinal in
the final model: the OR of time is thus to be interpreted
as the variation in the odds of PHN for every visit
increase (that is, the OR of PHN at the third, six-month
visit vs the second, three-month visit). It is important to
specify that the GEE model represented the main and
most reliable analytical approach to investigate the
potential predictors of PHN during follow-up.
To evaluate independent associations between pain
burden and other variables under investigation, a linear
regression analysis was used. The dependent variable of
the model was AUC, which was transformed into its
square root because of its skewed distribution (Shapiro-
Wilk test). Because of the incomplete follow-up for
some participants, the total follow-up duration was
included as a covariate into the final model, whose
validity was assessed as follows: the assumption of con-
stant error variance was checked graphically, plotting
Pearson residuals vs fitted values, and formally, using
Cook and Weisberg’s test for heteroskedasticity. High
leverage observations were identified using Pearson,
standardized and studentized residuals, Cook’sDi n f l u -
ence, Welsch distance and hat diagonal matrix [35].
High leverage observations were, however, < 5% of the
total sample with all methodologies, with no appreciable
changes on the final results after their exclusion (the
final model was therefore based upon the total sample).
All multivariate models reliability was also checked
using bootstrap estimation with 500 replications. The
bias-corrected bootstrap showed quite similar results for
all models, thus bootstrapped estimates were not shown
to avoid redundancy. Finally, in all multivariate analyses,
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imputation procedures were thus avoided. Statistical sig-
nificance was defined as a two-sided P-value < 0.05 for
all analyses, which were carried out using Stata version
10.1 (Stata Corp., College Station, TX, USA, 2007).
Results
Overall, 519 patients were enrolled, 68.0% by the GPs
and 32.0% by the Hospital Units. Microbiological inves-
tigation was requested for 63 subjects (12.1%), and HZ
was diagnosed in 28 of them. HZ was not confirmed for
the remaining 35 patients, who were excluded. Forty-
three subjects were also excluded because of diagnosis
of other dermatological diseases by expert review of
clinical and pictorial data (n = 6), insufficient data pro-
vided at the first visit (n = 9), consent withdrawal during
follow-up (n = 28). As a consequence, 441 patients were
followed for a mean of 335 days (SD = 82 days).
Twenty-four (5.4%) patients were hospitalized for a
mean of 9.3 (3.2) days; no patient died during follow-up.
The baseline characteristics of the sample are summar-
ized in Table 1. The mean age was 58.1 (20.4) years;
median age was 63 years; 43.5% of patients were males.
Rash was severe (> 50 vesicles) in 30.2% of the 278 eva-
luable patients. Median time between rash onset and
enrolment was three days (Interquartile Range, IQR, 3),
56% of patients being enrolled by the third day from
rash onset and 89.2% by the seventh day. For 63 (14.3%)
of 433 patients in the final sample a possibly relevant
comorbidity was reported: 39 solid tumours (8.8%),
10 leukemias or lymphomas (2.3%), 11 neurological dis-
orders (including Alzheimer disease, multiple sclerosis,
or peripheral neuropathies), and 6 mood disorders (all
major depression). In accordance with our study proto-
col, 406 patients were prescribed antivirals on the same
day of enrolment (acyclovir, n = 148; valacyclovir, n =
148; famcyclovir, n = 47; brivudin, n = 63); 35 patients
(7.9%) received no prescription of antiviral drugs, 5 as a
choice of the enrolling physician, 19 because of the fear
of allergic reactions in poliallergic patients, 11 for very
late presentation, that is very advanced rash evolution.
An overlapping distribution, far from reaching any sta-
tistically significant difference, was observed for all vari-
ables in the final sample and in the 37 patients excluded
due to insufficient data at inclusion or consent withdra-
wal during follow-up.
Correlates of pain intensity at presentation
Intense or very intense pain at presentation was
reported by 25.2% of the patients (n = 111; Table 2).
T h el o g i s t i cr e g r e s s i o na n a lysis showed that patients
reporting intense or very intense pain at presentation
were significantly more likely to be female, older, pre-
sent or past cigarette smokers, with history of trauma
and/or surgical intervention at the site of HZ. They also
reported more frequently taking analgesics in the acute
phase (all P < 0.05, Table 2). Rash severity could not be
considered in multivariate models because 163 patients
did not consent to pictorial documentation.
Predictors of PHN and overall pain burden
Pain was reported by 51.2% of patients at one month
after enrolment (n = 226); by 30.0% (n = 130) during
the time interval one to three months; by 9.8% (n = 43)
during the time interval three to six months; by 7.5%
(n = 33) during the time interval 6 to 12 months. The
frequency of PHN was clearly and tightly related to the
semi-quantitative grading of pain at presentation at the
one- and one- to three-month time points (Table 1,
Figure 1). PHN at one month was as low as 37.8% in
patients with mild pain at presentation, raising up to
82.1% in patients with very intense-intolerable pain.
Similar results were observed for the three to six
months and 6 to 12 months time intervals (Figure 1).
The results of the repeated measures analysis (GEE)
investigating potential independent predictors of PHN
during the follow-up are shown in Table 3. The associa-
tions observed at univariate analyses for age, pain at
presentation, smoking, trauma and missed antiviral pre-
scription (although borderline) were confirmed when
controlling for potential confounders. Expectedly, time
was highly and negatively associated with PHN, but
none of the interaction terms between time and any
PHN predictor achieved significance (neither the most
clinically relevant one, missing antiviral therapy-time,
which showed a P-value of 0.44).
We also reported the results of separate logistic
regression models investigating potential independent
predictors of PHN at one month and three months
(Table 4). The results of both models are mostly con-
cordant with those of the repeated measures model,
which is the main and most reliable analysis. These
additional logistic models were made only to facilitate
the comparison between our findings and those from
previous studies, the majority of which used such time
intervals.
An AUC was obtained for each patient. Age, pain
intensity at presentation, smoking, missed antiviral pre-
scription and trauma were significantly and indepen-
dently associated with total pain burden as measured by
the AUC in the final linear regression model (all P <
0.05, Table 5).
Discussion
Our prospective observational cohort study was aimed
at investigating pain intensity at the onset of HZ and its
correlates, as well as predictors of PHN and overall pain
burden in real-life clinical settings. Our study was
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Page 4 of 10Table 1 Selected demographic, behavioural and clinical characteristics of the final sample of HZ patients
Variables Overall
sample
(n = 441)
PHN one-month
definition
(n = 226)
No PHN one-month
definition
(n = 210)
P* PHN
three-month
definition
(n = 130)
No PHN
three-month
definition
(n = 304)
P*
Demographic
characteristics
Mean age in years (SD) 58.1 (20.4) 61.1 (18.8) 54.9 (21.7) 0.002 60.4(19.3) 57.0 (21.0) 0.12
%% % % %
Female gender 56.5 57.5 55.4 0.6 60.0 54.7 0.3
Married 76.4 79.6 73.2 0.10 83.1 73.3 0.02
Higher educational level 39.7 38.9 40.5 0.7 39.2 40.1 0.9
Anamnesis
Hypertension 36.0 39.4 32.6 0.14 33.8 36.8 0.7
Diabetes mellitus
(missing = 3)
9.1 10.7 7.5 0.2 8.6 9.1 0.9
HCV infection 1.4 2.2 0.5 0.11 1.5 1.3 0.8
HIV infection 1.1 1.8 0.5 0.2 1.5 1.0 0.6
Neoplasm (m = 8) 11.3 12.7 9.9 0.3 10.0 11.4 0.9
Neurological disorders 2.5 3.5 1.4 0.15 3.1 2.3 0.6
Psychiatric illnesses
(m = 17)
1.4 1.4 1.5 0.9 0.0 2.1 0.10
Allergy 10.9 15.5 6.1 0.001 16.1 8.8 0.025
Trauma (m = 3) 16.0 24.5 7.0 < 0.001 31.8 9.5 < 0.001
Surgical intervention
(m = 3)
31.0 41.5 20.1 < 0.001 46.9 24.5 < 0.001
Alcohol abuse (m = 7) 6.9 4.5 9.5 0.04 4.0 7.9 0.14
Current or former
smoking (m = 2)
26.0 32.4 19.2 0.002 38.0 20.9 < 0.001
Familial CHD risk (m = 2) 25.1 29.9 20.0 0.017 31.2 22.2 0.045
Clinical characteristics
HZ dermatomeric district
Thoracic 49.8 49.1 50.5 0.8 46.9 51.3 0.4
Lumbar 22.9 23.4 22.4 0.8 25.4 21.2 0.3
Cranial 18.2 20.8 15.4 0.14 19.2 18.0 0.8
Cervical 9.1 6.6 11.7 0.07 8.5 9.5 0.7
Pain intensity
Mild 40.5 30.1 51.6 < 0.001 26.1 46.9 < 0.001
Moderate 34.2 33.6 34.7 0.8 31.5 35.4 0.4
Intense 18.9 26.1 11.3 < 0.001 30.0 13.8 < 0.001
Very intense 6.4 10.2 2.3 < 0.001 12.3 3.9 0.001
> 50 vesicles (m = 163) 30.2 37.1 22.0 0.007 38.4 26.8 0.054
Missed prescription of
antivirals
7.9 11.9 3.7 0.001 16.1 4.6 < 0.001
Use of analgesics in the
acute phase
43.0 47.3 38.5 0.061 42.3 43.6 0.8
When no missing observations (m) are indicated, there were no missing values. * Chi-square test for categorical variables; t-test for continuous variables. Only the
variables reported in the table have been included in the model.
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support by pharmaceutical companies.
Pain intensity at presentation and its correlates
A quarter of the enrolled sample presented with intense
or very intense pain, according to the adopted semi-
quantitative five-degree scale. This percentage was lower
than the 41% rate of patients with severe or very severe
pain observed by Chidiac et al. in their prospective
cohort [3]. Other retrospective investigations were not
aimed at quantifying zoster-associated pain (ZAP) at
presentation and do not therefore provide a direct refer-
ence for this finding [1,2,4-7,17,18,20]. The proportion
of patients with intense or very intense pain at presenta-
tion may have been overestimated in our study if very
mild cases never requested medical assistance; there are
no reasons, however, to believe that differences between
possibly missed and included cases would be so relevant
as to substantially modify our evaluation of the corre-
lates of pain intensity at presentation as well as of PHN.
Intense pain at presentation was independently related
with age, female gender, present or former cigarette
smoking, trauma and/or surgery at the site of HZ.
Intense pain was also somewhat obviously associated
with more frequent use of analgesics at enrolment.
Some data suggest that the perception of pain from
myocardial ischemia is significantly less severe and
delayed in the elderly compared to younger patients
[38]. Furthermore, many clinical studies suggest a rela-
tive decrease in the frequency and intensity of pain
symptoms associated with myocardial complaints, visc-
eral infections, musculoskeletal conditions, and post-
operative and malignant pain problems in adults of
advanced age [39]. More closely related to our field,
data from prospective studies have demonstrated that
HZ patients with severe acute pain at presentation have
an increased risk of developing PHN, but few studies
have examined the relationships between acute pain
severity and age. Some studies even showed that older
age was not consistently associated with more intense
acute pain [12]. Our results, however, were clear-cut sig-
nificant: mean age was 55.6 years (SD = 21.7) in patients
Table 2 Results of the logistic regression model predicting intense/very intense pain at presentation
Intense/Very intense pain
(n = 111)
Mild/Moderate pain
(n = 330)
OR (95% CI) P
Mean age in years (SD) 65.4 (14.0) 55.6 (21.7) 1.02 (1.01 to 1.04)* < 0.001
%%
Female gender 69.4 52.1 2.50 (1.41 to 4.35) 0.002
Current/former smoking 33.3 23.5 2.00 (1.11 to 3.61) 0.021
Trauma 30.6 11.0 2.51 (1.30 to 4.84) 0.006
Surgical intervention 50.0 24.7 2.09 (1.21 to 3.62) 0.008
Use of analgesics in the acute phase 65.4 35.6 3.60 (2.17 to 5.98) < 0.001
* One-year increase.
Figure 1 Pain intensity at presentation and the risk of PHN at different time intervals. Proportion of patients developing PHN at different
time intervals according to pain intensity at presentation. Patients with PHN were 51.2% (n = 226) at one month after enrolment; 30.0% (n =
130) after one to three months; 9.8% (n = 43) after three to six months; 7.5% (n = 33) after 6 to 12 months.
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years (14.0) in those with intense of very intense pain;
54.9 years (21.7) in patients without PHN and 61.1 years
(18.8) in patients with PHN, both with confidence inter-
vals not overlapping at all. So they confirm those of
Dworkin et al., 2001, indicating that older age and rash
severity were associated with more severe acute pain
assessed within 72 h of rash onset [12]. Trauma or sur-
gery at the site of HZ has been already suggested as a
predictor of VZV reactivation [22-26]. Our estimate of
the proportion of patients reporting surgery in advance
of HZ (31%) is somewhat higher than that reported by
other authors, and this fact may be difficult to explain;
it cannot be related to any selection bias, however, as
patients were recruited by GPs or in medical wards of
the local hospital. Therefore, it is likely that this poten-
tial correlate, which was searched in the medical history
section at enrolment, may have been more systemati-
cally investigated in our setting than in others. In addi-
tion, surgical interventions have never been investigated
as a possible correlate of pain intensity and persistence
in HZ patients in a large cohort as ours [22-26]. Our
finding of a remarkable association between surgery and
trauma and pain intensity at presentation of HZ suggest
that nerve fibre impairment secondary to these events
m a yp r e d i s p o s et om o r ei n t e n s ep a i n .F e m a l eg e n d e r
has already been associated with a more intense percep-
tion of pain in several other clinical conditions, and
gender differences in clinical and experimental pain sen-
sitivity and response to pain treatment have been thor-
oughly investigated [40]. The status of being a present
or past smoker almost doubled the risk of intense pain
in our sample. A potential role for smoking in chronic
pain syndromes has been well documented [41].
Furthermore, smoking has been associated with frequent
s u b c l i n i c a lp e r i p h e r a ln e u ropathy in patients with
chronic obstructive pulmonary disease [42,43]. These
associations may be due to structural or functional
impairment of pain transmission by chronic smoking
habits [41]. Moreover, the association of smoking with
pain intensity might be due to smoke-induced impair-
ment of cell-mediated immunity, leading to more
aggressive viral activity during VZV reactivation [29]. In
our multivariate analyses, after several binomial and
multinomial logistic models suggesting a similar associa-
tion between current or past smoking and pain at pre-
sentation (data not shown), current and former smokers
were joined as a single group opposed to non smokers.
Our data would therefore suggest that the influence of
chronic cigarette smoking on pain at presentation may
persist even after quitting smoking. In any case, how-
ever, all the results on the association between smoking
and pain require confirmation from further research, as
we were not able to include in the analysis some
Table 3 Results of the generalized estimating equations
(GEE) model predicting PHN during the entire follow-up
Variables OR (95% CI) P
Age, ten-year increase 1.01 (1.00/1.02) 0.017
Female gender 0.91 (0.63/1.32) 0.6
Current/former smoking 1.50 (1.02/2.21) 0.039
Intense/very intense pain at presentation 1.85 (1.29/2.65) 0.001
Trauma 2.27 (1.48/3.46) < 0.001
Surgical intervention 1.40 (0.96/2.02) 0.081
Missed antiviral prescription 1.46 (1.00/2.25) 0.049
Time, one-visit increase 0.73 (0.68/0.78) < 0.001
OR = Odds Ratio
Table 4 Results of the logistic regression models predicting PHN at one and one to three months
PHN at one month PHN at one to three months
Variables OR (95% CI) P OR (95% CI) P
Age, ten-year increase 1.01 (1.00 to 1.02) 0.032 1.01 (0.99 to 1.02) 0.4
Female gender 1.05 (0.68 to 1.63) 0.8 1.39 (0.84 to 2.30) 0.2
Current/former smoking 1.62 (0.98 to 2.67) 0.061 2.08 (1.22 to 3.55) 0.007
Intense/very intense pain at presentation 2.41 (1.43 to 4.04) 0.001 2.19 (1.32 to 3.65) 0.003
Trauma 2.22 (1.12 to 4.39) 0.022 2.53 (1.37 to 4.65) 0.003
Surgical intervention 1.60 (0.98 to 2.63) 0.062 1.33 (0.79 to 2.25) 0.3
Missed antiviral prescription 2.01 (1.01 to 4.46) 0.047 2.28 (1.04 to 4.98) 0.038
OR = odds ratio
Table 5 Regression model predicting pain burden during
follow-up
Variables Coefficient (95% CI) P
Age, 10-year increase 0.03 (0.01/0.05) 0.004
Female gender 0.68 (-0.21/1.59) 0.14
Current/former smoking 1.50 (0.47/2.53) 0.004
Intense/very intense pain at
presentation
3.40 (2.37/4.43) < 0.001
Trauma 1.58 (0.31/2.85) 0.015
Missed antiviral prescription 2.22 (0.63/3.82) 0.006
Pain burden was calculated by multiplying pain intensity for its duration,
using the area-under-the-curve (AUC) method described in the text. The
dependent variable AUC was transformed into its square root to approach
normality.
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which have been associated to both higher HZ pain
intensity and smoking [10,44,45].
Predictors of PHN and total pain burden
The other major aim of our study was to consider and
quantify pain persisting any longer than rash healing,
looking for predictors of such persistence. Remarkable
differences exist as to the time interval considered for
the diagnosis of PHN [13-16,46]. Most authors so far
set at three or six months the threshold for PHN to be
diagnosed after rash healing or onset; in particular
Oxman et al. defined PHN as ZAP rated as ≥ 3o na
0-to-10 VAS scale and persisting or appearing > 90 days
after the rash onset [46]. To account for ZAP restricted
within this time frame, which involves over 30% of HZ
patients, PHN was diagnosed elsewhere when pain per-
sisted one month after rash onset or healing [8,14,47].
In the present study, pain was considered as a conti-
nuum and its total amount in the individual patient was
quantified using our AUC method rather than choosing
an arbitrary time threshold. To facilitate comparisons,
however, we diagnosed PHN qualitatively using both the
one-month and the one- to three-month thresholds.
Indeed, also the qualitative three- to six-month thresh-
old was considered and dropped, because of the yield of
identical results (data not shown). We, however, used a
GEE model as the main multivariate model to better
account for pain relapsing at later time points. The
accuracy of the AUC method that we used may not be
as high as that used by Coplan and Oxman et al., who
collected data concerning pain intensity much more fre-
quently than we did [33,46]. We diagnosed PHN when
pain of any degree persisted or relapsed at follow up vis-
its. We allowed progressively longer time intervals
among visits, up to six months between the last two vis-
its. This may have reduced accuracy in detecting PHN,
representing a limitation of our study design [48,49].
Pain in PHN, however, is long lasting and easy to inter-
pret even by ordinary culture people [49,50]. This may
have partly counterbalanced the underestimation of pain
caused by longer time intervals between follow-ups in
our series [50]. On the other hand, we may have overes-
timated PHN by the AUC method, as an intense pain
experience in the beginning of a broad time-window
may have been carried forward to the following distant
endpoint. As the AUC method, however, confirmed
results obtained with the logistic regression models and
with the repeated measures multivariate analysis, a pos-
sible overestimation of pain persisting in a few patients
is not likely to have biased our general conclusions.
A number of parameters have been proposed as pre-
dictors of PHN, pain intensity and age at presentation
being the only ones consistently emerging in most of
previous investigations [1,9,17-21]. We evaluated a large
array of items in patients’ history, clinical presentation
and therapy, and observed a strong association of PHN
with intense pain at presentation both at 1 month and
one- to three-month intervals, confirming acute pain
intensity as one of the most relevant predictors of pain
duration [1,17,18]. Age was similarly confirmed, adding
evidence that older age is associated not only with a
higher risk of VZV reactivation, but also with a higher
probability of pain persistence [1,9,12,17,18]. The aging
PNS and CNS may indeed poorly tolerate damage to a
reduced number of functional neurons, thus increasing
the likelihood of PHN development and duration.
Elderly persons are also likely to have concomitant dis-
eases and medications for their management [51]. As to
prodromal pain duration and rash severity, frequently
reported as tight predictors of PHN in previous studies,
these variables could not be included in our final models
because of the high proportion of missing values; this
likely represents one major limitation of our investiga-
tion. Three additional novel factors, however, were
found tightly associated with the total amount of pain
and PHN. First, a protective role of antiviral therapy,
prescribed any time during rash evolution and whatever
the drug of choice, emerged as statistically significant.
So far, the role of antiviral therapy was mainly investi-
gated in randomized controlled trials (RCT), including
only patients diagnosed within 72 hours from onset of
HZ [27,47], and its efficacy in preventing PHN has been
recently questioned by a meta-analysis including most
of the above mentioned trials [27]. Until recently,
indeed, HZ has been frequently considered a self limit-
ing disease [1,4,5,8,9] and antiviral therapy of debatable
usefulness [4,5,18,27,28]. This may well be the case if
the main aim of therapy would be reducing complica-
tions other than pain [52]. In the present cohort, in
which the role of antiviral therapy was examined in cur-
rent clinical practice, PHN was more frequent both at
one and one- to three-month intervals both in univari-
ate and multivariate analyses in the small proportion of
patients not prescribed antivirals, as well as in the
repeated measures multivariate analysis. Although the
design of the present study does not allow to draw any
firm conclusion about the effectiveness of antivirals with
respect to pain, as an RCT would be the appropriate
study design, our investigation confers an additional
clue that antivirals may reduce the total burden of pain
in the individual patient, even when prescribed beyond
the 72-hour time threshold, as in half of patients in our
series, in line with current clinical practice [10,21,47].
Second, major traumas were significantly associated
with the total amount of pain and PHN in all statistical
models. Traumas and work-related injuries have been
already associated with an increased risk of HZ [22-24].
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induce local changes facilitating VZV reactivation in
spinal ganglia and contributing also to more intense and
durable pain. Clearly, such an hypothesis should be
further investigated. Third, cigarette smoking emerged
as a predictor of pain persistence at all investigated time
points. This finding reinforces the significance of its
above discussed association with pain intensity at pre-
sentation. The same hypothesized impairment of pain
transmission pathways might be responsible for its per-
sistence. Further investigations, however, including
pathological and/or in vitro studies, will be necessary to
demonstrate a causal linkage. Our survey included a
very limited number of patients with comorbilities,
which are known to increase the risk of HZ. Such few
cases did not allow us to stratify our analyses for comor-
bid patients. However, our sample allows us to confirm
previous data, suggesting that most of incident cases of
HZ occur in otherwise healthy and relatively young
adults [6,7].
Conclusions
Our study provides new insights into the knowledge of
pain intensity at presentation and pain persistence due
to HZ in a large, monocentric, prospective cohort of
unselected Caucasian patients. Cigarette smoking, trau-
mas and surgery at the site of the HZ emerged as new
predictors of both intensity and persistence of pain, all
of which may well deserve further investigation. A new,
independent line of evidence is provided as to the effi-
cacy of antiviral therapy in reducing the incidence of
PHN and the total burden of pain caused by HZ.
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